Biocad

Russia - St. PetersburgBiotechnology1 H-1B visas (FY2023)

Focus: Biocad is a Russian biotechnology company specializing in biosimilars and innovative biologics across oncology, immunology, and rare diseases. The company operates a diversified pipeline of 30+ programs with multiple Phase 3 assets.

Oncology Immunology Neurology Infectious Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Biocad

AI assessmentNot Hiring

No open roles listed right now. Follow Biocad to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

Levilimab

COVID-19 and Rheumatoid Arthritis

Growth

IL-6 receptor antagonist in Phase 3 for two indications; represents in-house innovation beyond biosimilars.

Empegfilgrastim

Chemotherapy-Induced Neutropenia

Help build intelligence for Biocad

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

Empegfilgrastim

Patients With Solid Tumours Who Receive Myelosupressive Therapy

N/A

Clinical Trials (1)

NCT04811443DEFENDOR: A Multicenter Prospective Observational Post-registration stuDy of Extimia® (INN: empEgfilrastim) to Evaluate Efficacy and saFEty in patieNts With soliD tumORs

N/A

BCD-145

Melanoma

Phase 1

Clinical Trials (1)

NCT03472027Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma

Phase 1

BCD-256

Systemic Lupus Erthematosus

Phase 1

Clinical Trials (1)

NCT07136389Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus

Phase 1

Bevacizumab

Neovascular Age-related Macular Degeneration

Phase 1

Clinical Trials (1)

NCT02450981Evaluation the Pharmacokinetics, Safety, Tolerability of BCD-021 in Patients With Neovascular Age-related Macular Degeneration

Phase 1

Adalimumab

Healthy

Phase 1

Clinical Trials (1)

NCT02395055Comparative Clinical Study of Pharmacokinetics, Tolerance and Safety of BCD-057 and Humira in Healthy Volunteers

Phase 1

BCD-264

Healthy

Phase 1

Clinical Trials (1)

NCT05974969A Study to Assess the PK, PD, Safety and Immunogenicity of Single IV Infusion of BCD-264 and Darzalex in Healthy Subjects

Phase 1

Adalimumab

Healthy Adult Male

Phase 1

Clinical Trials (1)

NCT07181694A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects

Phase 1

Leucostim®

Leucocytosis

Phase 1

Clinical Trials (1)

NCT02762799Clinical Trial to Evaluate Pharmacokinetics, Pharmacodynamics and Safety of Leucostim® Compared to Neupogen®

Phase 1

BCD-089

Healthy

Phase 1

Clinical Trials (1)

NCT03103438First-in-human Study of Safety, Pharmacokinetics and Pharmacodynamics of Various Doses of BCD-089 in Healthy Subjects

Phase 1

BCD-066

Healthy

Phase 1

Clinical Trials (1)

NCT03693950The Study of PK, PD, Safety of Multiple Intravenous Injections of BCD-066 and Aranesp in Healthy Volunteers

Phase 1

BCD-147

Healthy

Phase 1

Clinical Trials (1)

NCT03912441First-In-Human Study to Evaluate Safety And Pharmacokinetics of Single Escalating Doses of BCD-147 (Bispecific Anti-HER2/HER2 Antibody) in Healthy Subjects

Phase 1

BCD-201

Melanoma

Phase 1

Clinical Trials (1)

NCT05739006Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies

Phase 1

BCD-115

Breast Cancer

Phase 1

Clinical Trials (1)

NCT03065010Study of BCD-115 in Women With ER(+) HER2(-) Local Advanced and Metastatic Breast Cancer

Phase 1

Darbepoetin alfa

Healthy

Phase 1

Clinical Trials (1)

NCT02506881Pharmacokinetics and Pharmacodynamics Study of BCD-066 Compared to Aranesp® in Healthy Volunteers

Phase 1

BCD-054

Healthy

Phase 1

Clinical Trials (1)

NCT02359877Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers

Phase 1

Infliximab

Ankylosing Spondylitis

Phase 1

Clinical Trials (1)

NCT02359903Comparative Evaluation of Pharmacokinetics and Safety of BCD-055 and Remicade in Patients With Ankylosing Spondylitis

Phase 1

BCD-261

Healthy Adult Participants

Phase 1

Clinical Trials (1)

NCT07535775Evaluate Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of BCD-261 After Single Subcutaneous Injection in Healthy Chinese Volunteers

Phase 1

BCD-178

Breast Cancer

Phase 1

Clinical Trials (1)

NCT05738993A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy Volunteers

Phase 1

BCD-148

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT04027803Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®

Phase 1

BCD-135

Melanoma

Phase 1

Clinical Trials (1)

NCT03464032A Study of BCD-135 in Patients With Advanced Solid Tumors

Phase 1

BCD-132

Multiple Sclerosis

Phase 1

Clinical Trials (1)

NCT03551275Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis

Phase 1

BCD-100

Melanoma

Phase 1

Clinical Trials (1)

NCT03050047A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors

Phase 1

BCD-245

Neuroblastoma

Phase 1

Clinical Trials (1)

NCT05782959Phase 1 Study of BCD-245 in Subjects With Neuroblastoma

Phase 1

BCD-263

Advanced Melanoma

Phase 1

Clinical Trials (1)

NCT06112808A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin

Phase 1

Interferon beta-1a

Healthy

Phase 1

Clinical Trials (1)

NCT01766024Pharmacokinetics and Pharmacodynamics Study of BCD-033 Compared to Rebif® in Healthy Volunteers

Phase 1

humanized monoclonal antibody against human IL-17

Healthy

Phase 1

Clinical Trials (1)

NCT02380287First-in-human Study to Evaluate Safety, Tolerability and Pharmacokinetics of Various Doses of BCD-085 in Healthy Subjects

Phase 1

BCD-180, dose 1

Healthy

Phase 1

Clinical Trials (1)

NCT05407779Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of Single Escalating Doses of BCD-180 in Healthy Volunteers

Phase 1

BCD-131

Reticulocyte Count

Phase 1

Clinical Trials (1)

NCT02731469Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers

Phase 1

BCD-121

Healthy

Phase 1

Clinical Trials (1)

NCT03103451First-in-human Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Doses of BCD-121 in Healthy Subjects

Phase 1

BCD-261, dose 1

Healthy

Phase 1

Clinical Trials (1)

NCT06715540Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Ascending Doses BCD-261 in Healthy Subjects

Phase 1

ANB-010, dose 1

Hemophilia A

Phase 1/2

Clinical Trials (1)

NCT06185335A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A

Phase 1/2

ANB-002, dose 1

Hemophilia B

Phase 1/2

Clinical Trials (1)

NCT06120582Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN)

Phase 1/2

Low dose BCD-250 injection

Coronavirus Infection

Phase 1/2

Clinical Trials (1)

NCT05037188Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5 )-RBD (Receptor Binding Domain)-S Vaccine for the Prevention of Coronavirus Infection (COVID-19)

Phase 1/2

ANB-004, dose 1

Spinal Muscular Atrophy (SMA)

Phase 1/2

Clinical Trials (1)

NCT05747261Study of the Safety and Efficacy of an Adeno-Associated Viral Vector Carrying the SMN Gene After a Single Intravenous Administration of Escalating Doses in Children With Spinal Muscular Atrophy (BLUEBELL)

Phase 1/2

anti-TRBV9 monoclonal antibody, low dose

Axial Spondyloarthritis

Phase 2

Clinical Trials (1)

NCT05445076Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis

Phase 2

BCD-217

Melanoma

Phase 2

Clinical Trials (1)

NCT03913923Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma

Phase 2

anti-TL1A monoclonal antibody, low dose

Ulcerative Colitis (UC)

Phase 2

Clinical Trials (1)

NCT07080034Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative Colitis

Phase 2

BCD-131

Anemia

Phase 2

Clinical Trials (1)

NCT03519243Comparative Study of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in CKD Patients on Dialysis

Phase 2

BCD-085

Ankylosing Spondylitis

Phase 2

Clinical Trials (1)

NCT02763111Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis

Phase 2

BCD-085

Psoriasis

Phase 2

Clinical Trials (1)

NCT02762994International Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Moderate to Severe Plaque Psoriasis

Phase 2

anti-TL1A monoclonal antibody, low dose

Crohn's Disease (CD)

Phase 2

Clinical Trials (1)

NCT07078994Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease

Phase 2

BCD-085

Liver Cirrhosis, Biliary

Phase 2

Clinical Trials (1)

NCT03476993Non-comparative Study of BCD-085 in Combination With UDCA in Patients With Primary Biliary Cholangitis

Phase 2

BCD-248

Relapsed/Refractory Multiple Myeloma

Phase 2

Clinical Trials (1)

NCT06668792An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma

Phase 2

empegfilrastim

Chemotherapy-induced Neutropenia

Phase 2

Clinical Trials (1)

NCT01569087Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer

Phase 2

BCD-132, 125 mg

Multiple Sclerosis

Phase 2

Clinical Trials (1)

NCT04056897Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis

Phase 2

BCD-089, 162 mg, s/c, qw

Seropositive RA

Phase 2

Clinical Trials (1)

NCT03455842The BCD-089 (aIL6R) in Patients With Active Rheumatoid Arthritis

Phase 2

BCD-236

Triple Negative Breast Cancer

Phase 2

Clinical Trials (1)

NCT07108309BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer

Phase 2

BCD-100

Cervical Cancer

Phase 2

Clinical Trials (1)

NCT03912402Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)

Phase 2

BCD-100

Melanoma

Phase 2

Clinical Trials (1)

NCT03269565International Trial of the Efficacy and Safety of BCD-100 in Patients With Melanoma

Phase 2

BCD-033

Multiple Sclerosis

Phase 2/3

Clinical Trials (1)

NCT02727907Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis

Phase 2/3

Biocad

About Biocad

Why Work Here

Key Products

Watch Out For

Pipeline & Clinical Trials

Open Jobs (0)

Visa Sponsorship